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Abstract 
Adenosine receptors are G-protein-coupled receptors involved in a wide range of 
physiological and pathological phenomena in most mammalian systems. All four 
receptors are widely expressed in the central nervous system, where they modulate 
neurotransmitter release and neuronal plasticity. A large number of gene association 
studies have shown that common genetic variants of the adenosine receptors 
(encoded by the ADORA1, ADORA2A, ADORA2B and ADORA3 genes) have a 
neuroprotective or neurodegenerative role in neurologic/psychiatric diseases. New 
genetic studies of rare variants and few novel associations with depression or 
epilepsy subtypes have recently been reported. Here, we review the literature on the 
genetics of adenosine receptors in neurologic and/or psychiatric diseases in humans, 
and discuss perspectives for further genetic research. We also provide an update on 
the genetic structures of the four human adenosine receptor genes and their 
regulation - a topic that has not been extensively addressed. Our review emphasizes 
the importance of (i) better characterizing the genetics of adenosine receptor genes 
and (ii) understanding how these genes are regulated. 
  
Introduction 
Adenosine exerts a variety of physiological effects in most mammalian systems 
through four subtypes of G-protein-coupled adenosine receptors (A1R, A2AR, A2BR, 
and A3R), each of which is encoded by their own gene (ADORA1, ADORA2A, 
ADORA2B, and ADORA3, respectively). The four adenosine receptors are widely 
expressed in the central nervous system (CNS) in general and in neurons, glial cells 
and endothelial cells in particular.1,2 In the CNS, A1R and A2AR modulate synaptic 
neurotransmission through their action on the release of various neurotransmitters 
(such as glutamate, γ-aminobutyric acid, acetylcholine and dopamine) and on the 
activation of postsynaptic receptors. Excitatory transmission is inhibited by A1R 
activation and stimulated by A2AR activation. The interplay between these two 
receptors helps to fine-tune synaptic plasticity.3 In several regions of the brain, the 
two receptors are co-expressed and can form heteromers together4 or with other G-
coupled receptors, such as dopamine receptors.5,6 Neuroprotective and 
neurodegenerative effects of A1R and A2AR have been observed in various 
neurologic diseases (Parkinson’s disease, Huntington’s disease, migraine, stroke, 
and epilepsy) and psychiatric diseases (schizophrenia, panic disorders, depression, 
and autism).7,8 A2BR is widely expressed in many tissues, and is involved in ischemia-
reperfusion injury, fibrosis, cancer, inflammation, and the immune system.9 Lastly, 
A3R is involved in the modulation of ischemic diseases, inflammatory diseases, 
cancer, autoimmune diseases, and chronic neuropathic pain.10 Until recently, A2BR 
and A3R were considered to have a minor physiological role because they have 
substantially lower affinities for adenosine and thus require higher extracellular 
adenosine concentrations for maximal activation. Only two studies have assessed 
them as genetic factors in human neurologic diseases.11,12 
Various aspects of adenosine receptor research and the receptors’ roles in the 
pathophysiology of the neural system, widely discussed in the current literature,8 lead 
to numerous publications assessing the role of genetic variants in adenosine receptor 
genes and neurological or psychiatric diseases. Recent advances in these fields 
(including new topics with the studies of rare genetic variants12,13 and new 
associations with epilepsy and depression14,15 highlight the importance of genetic 
variants in adenosine receptor gene in CNS disorders.  
Previous reviews or book chapters focused on the genes structure,16 on 
neurobiology,17 or on one specific gene and its neuroprotective/neurodegenerative 
effects.18,19 However, these previous works do not integrate and discuss all the 
genetic associations reported so far. It remains difficult to have a critical overview of 
the neurogenetics of adenosine receptor genes with the heterogeneity of the genetic 
studies (in diseases, sample size, methodologies and level of evidence). This 
prompted us to review the current state of knowledge regarding genetic associations 
of variants in adenosine receptor genes with human brain diseases and to confront 
them to functional assessment of the variants.  
 
 
The criteria and databases used for this literature search are given as supplementary 
material. 
ADORA1 
Gene structure (Figure 1.A) 
The human ADORA1 gene was cloned in 1992 from a hippocampal cDNA library.20,21 
It spans 77 kb, and is located on chromosome 1q32.1.22 The gene comprises six 
exons that undergo alternative splicing and alternative promoter usage.23,24 The 
Genotype-Tissue Expression (GTEx) database25 indicates that ADORA1 mRNAs are 
found in all tissues, with the highest expression levels in the spinal cord, brain (the 
frontal cortex, substantia nigra, and all the basal ganglia) and testis. 
According to the GENCODE database,26 the human ADORA1 gene encodes six 
different mRNAs (Figure 1.A). Three transcripts with different 5' untranslated regions 
(UTR) share the same coding exons (5 and 6), and yield a full-length 326-aa protein. 
The fourth transcript does not include exon 5, but contains an open reading frame 
(ORF) and might result in an N-terminal-truncated 210-aa protein. The two last 
transcripts contain exon 6 with an alternative 3' splice site, and are thought to encode 
a C-terminal-truncated 125-aa protein. Ren & Stiles showed that transcripts including 
exon 4 were widely expressed, whereas transcripts with exon 3 were present in the 
testis, kidney, fetal brain, and the frontal cortex and cerebellum of the adult brain but 
not in fat, skeletal muscle or heart.23 Two alternative promoters with nonclassical 
TATA boxes have been found upstream of exons 3 and 4.24,27 The promoter 
upstream of exon 3 is constitutively expressed at low levels, and contains a binding 
site for nuclear factor-kappa B (NF-κB),28 serum response factor and activator 
protein 1.29 The promoter upstream of exon 4 is more active but shows tissue-
specific regulation and contains a site for an AGG element binding protein.30 It is 
noteworthy that ADORA1 has only one upstream 262 bp CpG island, which overlaps 
with exon 4. Interestingly, there are two upstream AUG codons in exon 4, both of 
which are crucial for mRNA processing and translation. Indeed, mutations in these 
AUG codons are associated with greater levels of translation.24 We hypothesized that 
an upstream ORF (uORF) exerts post-transcriptional control on ADORA1 transcripts 
including exon 4 in the same way that uORF5 regulates ADORA2A expression.31 
Lastly, the ENCODE chromatin state segmentation from the University of California 
Santa Cruz Genomics Institute (UCSC) genome browser suggests that a third 
promoter is located upstream of exon 1.32 
 
Genetic risk factor in human diseases 
Psychiatric diseases 
In 2009, Gotoh et al. published a case control study including 200 schizophrenic 
patients and 210 controls. The researchers looked for an association between 29 
single-nucleotide polymorphism (SNPs) in ADORA1 and the presence of 
schizophrenia in a Japanese population.33 None of the individual SNPs was 
significantly associated with the disease and the small number of samples did not 
allow the identification of linkage disequilibrium blocks. However, a multivariate 
analysis evidenced an association with three haplotypes built from two or three 
SNPs. An important limitation concerned the control population who did not perfectly 
matched to the schizophrenic population. Moreover, our literature database search 
did not found a replication study in other Japanese population.  
A case-control study focused on the association between ADORA1 and ADORA2A 
SNPs and Tourette syndrome including 162 patients and 270 controls.34 Patients with 
a GG or GT genotype at rs2228079 were underrepresented. This silent SNP (located 
in exon 5) was associated with earlier age at tic onset and a greater prevalence of 
comorbidities (the concomitant presence of depression or obsessive compulsive 
disorders). However these comorbidities concerned only a small number of patients 
with particular psychiatric disorder. Moreover, the data about the earlier age at tic 
onset and comorbidities in some adult patients were retrospective.  
In a study of 806 Caucasian Americans, Clark et al. compared the number of alcohol 
dependence symptoms with the presence of variants in 71 candidate genes 
(including the coding, flanking and regulatory regions).13 Although the researchers 
did not find a significant association with the common variants considered in isolation, 
alcohol dependence was linked to an aggregate of eight variants (five rare variants 
and three common) within intron 5 of the ADORA1 gene. This study focused on 
common and rare variants and their aggregation on putative regulatory regions in the 
genes is original, but lacks functional validation and still need to be replicated.  
These three studies lack functional data and are balanced by negative results 
provided similar case-control studies evidencing no genetic association between 
ADORA1 SNPs and bipolar affective disorders35 or methamphetamine dependence 
or psychosis.36 Moreover, the role of ADORA1 common variant in anxiety disorders 
does not seem to be important regarding the study of Rogers et al. who did not found 
an association between seven ADORA1 SNPs and effects of caffeine (an antagonist 
of A1R) on anxiety.
37 Lastly, recent genome-wide association studies (GWAS) on 
schizophrenia,38,39 Tourette syndrome40 and alcohol dependence41 did not replicate 
these associations. The genetic associations of ADORA1 common variants in 
psychiatric diseases remain controversial and should then be interpreted with 
caution. 
  
Neurologic and neurodegenerative disorders 
ADORA1 mutations are thought to have a causal role in familial Parkinson's 
disease.42 In a study of a large consanguineous family in which two members were 
affected by early-onset Parkinsonism and cognitive dysfunction, Jaberi et al. used 
homozygosity mapping and exome sequencing to detect a homozygous missense 
mutation c.835G>A, p.(Gly279Ser) in exon 6 of the ADORA1 gene. Segregation 
analyses, bioinformatics predictions and the variant’s rarity made this missense a 
good candidate. However, the Gly279Ser variant did not have a functional effect on 
the interaction between A1R and the dopamine D1 receptor. Based on these genetic 
studies, and given A1R’s role in neurodegenerative diseases, Jaberi et al. 
hypothesized that ADORA1 was a reasonable candidate disease-causing gene. 
Moreover, the researchers suggested that ADORA1 was located within the 
Parkinson’s disease locus PARK16, which has been identified in several populations 
in earlier GWAS.43,44 However, it was later demonstrated that ADORA1 was not in 
the PARK16 locus, and that mutations in ADORA1 could not drive the PARK16 
association signal.45 Moreover, Jaberi et al. identified another homozygous variant in 
PTRHD1 that was later reported as a more likely candidate disease-causing gene. 
Indeed, Khodadadi et al. reported a different mutation in PTRHD1 in their study of 
another Iranian family with a similar clinical presentation.46,47 ADORA1 variants are 
not a common cause of Parkinson's disease or dementia with Lewy bodies45 and the 
role of the Gly279Ser variant in early-onset Parkinsonism with cognitive dysfunction 
is subject to debate. 
Variants in ADORA1 are associated with susceptibility to epilepsy after severe 
traumatic brain injury.48 In a retrospective study of 206 patients with severe traumatic 
brain injury (excluding penetrating head injury), Wagner et al. genotyped 6 SNPs in 
ADORA1. There was an association between the AA genotype at rs3766553 and an 
elevated incidence of early post-traumatic seizures, whereas the GG genotype at 
rs3766553 and the CT genotype at rs10920573 were associated with an elevated 
incidence of late-onset seizures. However, the study was not informative regarding 
the risk to develop recurrent seizures.  
To conclude, whereas the role of ADORA1 in rare Mendelian cause of Parkinsonism 
has been questioned if not refuted; the role of ADORA1 common variants in epilepsy 
after traumatic brain injury seems promising and might lead up to a better risk 
stratification and maybe to the development of new therapeutic strategies. 
 
ADORA2A 
Gene structure (Figure 1.B) 
Of the four human adenosine receptor genes, ADORA2A has the most complex 
structure. It was first cloned from a hippocampal library in 1992.49 It is 24 kb long, and 
is located on chromosome 22q11.23.50–52 Gene expression for ADORA2A mRNA has 
been evidenced in many tissues, including the liver, heart, lung, immune system, and 
brain.53 In the GTEx project,25 ADORA2A mRNAs were found to be expressed in all 
tissues; the highest expression levels were observed in the basal ganglia (the 
nucleus accumbens, putamen, and caudate), blood, spleen, lung, and cerebellum. 
ADORA2A is composed of two invariant coding exons and several alterative exons 
involved in the formation of a 5'-UTR. Using molecular and bioinformatics analyses, 
Yu et al. identified new exons encoding the 5'-UTR of ADORA2A in the mouse and in 
the human.54 In the human, the researchers evidenced six variants of non-coding 
exon 1, and referred to the invariant coding exons as exons 2 and 3. All transcripts 
encoded the same protein but displayed tissue-specific expression patterns. Kerth et 
al. identified eight 5'-UTR splice variants of ADORA2A produced by the alternative 
transcription and/or splicing of five noncoding exons upstream of the two invariant 
coding exons.55 In the Ensembl database, ADORA2A mRNAs have eight different 
transcription start sites (TSSs) (Figure 1.B), and non-coding RNAs give rise to three 
other TSSs. Not all the transcripts have been fully sequenced, and levels of evidence 
are low for some. In the GENCODE database,26 ADORA2A has four transcripts with 
an alternative 5'-UTR encoding the same 412-aa protein (Figure 1.B).  
Accordingly, the several putative promoter regions have not yet been extensively 
characterized. Most studies to date have been performed in the rat56–59 or the 
mouse.54 A few researchers have sought to characterize the human promoters60,61, 
mostly by focusing on a 2000 bp region of upstream of exon 2. By considering the 
histone code and the chromatin state segmentation data62 from the ENCODE 
project,63 we observed five non-overlapping promoter regions. As determined by the 
CpG Islands Track Settings tool (UCSC), only one promoter region comprises a 
1272 bp CpG island encompassing different alternative first non-coding exons 
(Figure 1.B). Methylation of this CpG island and the surrounding CpG shore was 
assessed in human brain samples from healthy individuals,64–66 patients with 
Huntington’s disease (HD),67 and schizophrenic patients68 - demonstrating that 
ADORA2A’s promoters are under epigenetic control. It is very likely that each 
promoter region has different transcription factor binding sites; these might control 
the expression of the ADORA2A gene under various conditions (e.g. as a function of 
the cell type, the development stage and/or the response to different stimuli). 
This complexity is heightened by the existence of different 5’-UTRs, which might 
recruit different RNA-binding proteins and thus regulates the degradation, storage, 
and/or translation of the corresponding ADORA2A mRNAs.69 In the rat, the different 
5’-UTRs can repress translation via the use of a conserved ORF (notably in humans) 
located 65 nucleotides upstream of the usual translation initiation site.70 Moreover, 
the rat uORF leads to the translation of a 134-aa protein called uORF5.71 Hence, the 
ADORA2A gene is a rare example of a human dual-coding gene. 
Yu et al. reported on a novel transcript that reads in the opposite direction to the 
ADORA2A gene.54 Indeed, there appears to be an antisense non-coding RNA gene 
(ADORA2A-AS1) at the same locus. Three isoforms of ADORA2A-AS1 have at least 
one exon that complements part of the ADORA2A UTR. Lastly, read-through 
transcription between the upstream SPECC1L gene (coding for sperm antigen with 
calponin homology and coiled-coil domains 1-like) and ADORA2A has been reported. 
This SPECC1L-ADORA2A transcript results in a non-coding RNA that probably 
induces nonsense-mediated mRNA decay and is then unlikely to produce a protein.72 
The functions of SPECC1L-ADORA2A and ADORA2A-AS1 are unknown but as 
other long non-coding RNAs (lncRNA), they might regulate different genes in the 
same locus, including ADORA2A. Indeed, the lncRNAs are known as regulator of 
gene expression modulating the transcription, splicing, and translation of other mRNA 
by RNA-DNA or RNA-RNA interaction.73 They have been implicated in numerous 
psychiatric/neurologic diseases, in neurodevelopment and neurodegeneration.74,75 
Then, genetic variants in these non-coding genes can (i) be in linkage disequilibrium 
with other more relevant variant in ADORA2A, (ii) be also located in an important 
region for the regulation of ADORA2A, like an enhancer and then modulate its 
transcription, but it is likely that (iii) some genetic variants affecting the expression of 
SPECC1L-ADORA2A or ADORA2A-AS1 could indirectly modify the expression of 
genes regulated by these lncRNAs. For example, ADORA2A-AS1 might form RNA 
duplexes with ADORA2A mRNA whereas SPECC1L-ADORA2A could induce 
epigenetic changes in ADORA2A.  
 
Genetic risk factor in human diseases  
Psychiatric diseases 
From 1998 onwards, ADORA2A variants were suspected to confer susceptibility to 
various anxiety disorders (e.g. panic disorder).76 In an initial comparison between 89 
German patients with panic disorder and matched controls, researchers observed a 
significant association of the disease with the T allele and the TT genotype of a silent 
SNP (rs5751876) located in ADORA2A exon 3. Later, Hamilton et al. highlighted a 
genetic linkage between panic disorder (especially the form with agoraphobia) and a 
haplotype encompassing rs5751876.77 All the significantly associated haplotypes 
comprised the C allele of rs5751876; this contradicted Deckert et al.’s report that the 
rs5751876 T allele was associated with an elevated risk of anxiety disorder. This 
discrepancy suggests that rs5751876 is not a causal variant conferring an elevated 
risk of anxiety disorder. Furthermore, it has also been reported that rs5751876 is 
associated with (i) various anxiety-related personality types76 and (ii) 
psychophysiological markers of anxiety-related arousal of the sympathetic nervous 
system in blood-injury phobia.78 The same research group replicated the association 
between rs5751876 (the TT genotype) and panic disorder.79 Again, the researchers 
found a stronger association in the agoraphobia subgroup - prompting them to 
suggest that the association with the panic disorder population as a whole might 
originate in this subgroup alone. Hohoff et al. found an association between an 
anxious personality and a haplotype composed of eight SNPs in ADORA2A 
(including rs2298383 and rs5751876). In one study rs2298383 was not associated 
with panic disorders in the absence of agoraphobia.80 However, a post hoc power 
analysis showed that the study including 71 patients and 100 controls was not 
powered to reliably detect a true association. Studies of different anxiety arousal 
paradigms in healthy subjects (such as caffeine-induced anxiety81,82 and anxiety 
response to amphetamine83) also highlighted an association with ADORA2A variants. 
Recent studies have highlighted a complex interaction between ADORA2A genetic 
variants and anxiety/attentional responses linked to caffeine.37,84–86 Taken as a 
whole, these data provide strong evidence for a role of the ADORA2 gene in anxiety 
disorders, and fit with the abnormally high level of anxiety in Adora2a-knockout 
mice.87 Most of these studies were conducted in Caucasian cohorts, and the 
association between rs5751876 and anxiety disorders was not replicated in two case 
control studies conducted in Chinese88 or in Japanese89 populations (respectively, 
104 cases versus 192 controls; and 91 cases versus 100 controls) - suggesting that 
the association is ethnicity-dependent. These findings also suggest that rs5751876 
(the most widely studied ADORA2A polymorphism) is not the causal variant 
conferring an elevated risk of anxiety; in fact, it is probably a tag SNP for the true 
causal variant. The latter might therefore be less frequent and/or not in linkage 
disequilibrium with rs5751876 in Asian populations. Another hypothesis is that 
ADORA2A confers susceptibility to anxiety in some patient subgroups (e.g. patients 
with agoraphobia).77,79 Another example was provided in 2012 by Subaran et al., who 
described an association with rs5751876 and rs4822492 in a subset of patients with 
panic disorders and bladder syndrome (n=92) but not in the whole cohort of patients 
with panic disorder (n=351).90  
Molero et al. studied the relationship between six ADORA2A polymorphisms in strong 
linkage disequilibrium and attention-deficit hyperactivity disorder traits.91 After 
correction for multiple comparisons, the rs35320474 SNP was still significantly 
associated with inattention symptoms but not with hyperactivity-impulsivity. Very 
recently, Fraporti et al. confirmed the association between the TT genotype of 
rs2298383 and the presence of anxiety disorders in children with attention-deficit 
hyperactivity disorder.92  
Janik et al. reported a link between ADORA1, ADORA2A and Tourette syndrome.34 
The T allele of rs5751876 was overrepresented among patients, and was associated 
with earlier age at onset. However, in contrast to previous studies, the T allele was 
underrepresented in patients with concomitant attention-deficit hyperactivity disorder 
and patients with anxiety but not obsessive-compulsive disorder. The later result was 
more questionable as it was obtained on small samples including only 128 non 
anxious patients with Tourette syndrome versus 34 anxious patients.  
Freitag et al. linked several ADORA2A SNPs to autism spectrum disorders (ASD) in 
a genetic case-control analysis of 98 patients and 234 controls.93 The CC genotype 
of rs2236624 (located in intron 3) was overrepresented in this group of patients. 
Increased current social interaction, nonverbal communication and repetitive 
behavior scores were associated with rs3761422 (CT and TT genotypes), rs5751876 
(CT and TT genotypes), and rs35320474 (T/del and del/del genotypes). Lastly, the 
researchers evidenced a significant association between a haplotype of eight SNPs 
(including rs5751876) and anxiety in the group of 98 patients with ASD. The most 
frequent haplotype ACTCCCTG (built with the rs5751862, rs5760405, rs2298383, 
rs3761422, rs2236624, rs5751876, rs35320474 and rs4822492 variants) was carried 
by 73.3% of the patients with severe anxiety disorders but only 33.9% of the patients 
without a history anxiety. However, it should be noted that although the allele C of 
rs5751876 was significantly less frequent in autism patients, it was overrepresented 
in the subset of individuals with a history of anxiety. 
The genetic link between ADORA2A and psychosis is more subject to debate. In a 
study of small number of schizophrenic patients (n=18) and healthy controls (n=33), 
Jagannathan et al. evaluated the relationship between gray matter volume (as 
measured using structural MRI) and 367 different SNPs in candidate genes.94 The 
researchers found an inverse correlation between a lack of gray matter in the frontal, 
temporal and thalamic regions (previously reported to be altered in schizophrenia) 
and 18 SNPs in 16 genes, including rs3761422 in ADORA2A. However, it had 
previously been reported that ADORA2A variants (including rs5751876) were not 
involved in the development of schizophrenia.95–97 The absence of a relationship was 
confirmed by two recent GWASs of patients with schizophrenia.38,39 
Recently, Oliveira et al. published the results of a cross-sectional population-based 
study of 1253 participants, of whom 228 were experiencing current depression.15 The 
TT genotype of rs2298383 was less frequent in patients experiencing current 
depression than in controls. After adjusting for confounding variables, this association 
remained significant (odds ratio (OR) [95% confidence interval (CI)]=0.631 [0.425‒
0.937]; p=0.022). The TT genotype was associated with protection against sleep 
dysfunction and attentional impairment - two common symptoms observed in patients 
with depression. However, an earlier case-control study performed in an Asian 
population and including 192 mood disorder patients and 216 controls did not 
evidence an association between rs5751876 and major depression or bipolar 
disorder.98 
 Neurologic and neurodegenerative disorders 
In 2007, ADORA2A was linked to migraine with aura.99 A haplotype block spanning 
the rs5760405, rs5751876, rs35320474, rs5751862, rs3761422 and rs4822492 
SNPs in ADORA2A was tested in 265 patients with migraine (of whom 122 had 
migraine with aura) and 154 controls. A GCCCTG haplotype was more frequent in 
patients suffering from migraine with aura than in controls. However, there was no 
significant difference between patients with migraine without aura and controls. 
Genetic variants in the ADORA2A gene are known to be genetic modifiers in the 
pathogenesis of HD, a hereditary neurodegenerative disorder caused by the 
expansion of CAG repeats within the HTT gene. The broad range of ages at onset is 
mostly explained by the number of CAG repeats but is also related to various 
environmental and genetic factors - including ADORA2A polymorphisms. A study 
published in 2009 reported an earlier age at onset (by 3.8 years) in patients with the 
TT genotype at rs5751876 than in patients with the CC genotype (p=0.02).100 The 
impact of ADORA2A genotype on residual variation was modest; however, these 
results have been replicated in two other studies.101,102 One of the latter found that 
rs2298383 in intron 1 (in linkage disequilibrium with rs5751876) to be the most 
strongly associated ADORA2A variant.101 These findings are supported by our 
knowledge of other environmental modifiers of HD (such as caffeine intake103) and 
data from animal models on the roles of A1R and A2AR.
104  
Horgusluoglu-Moloch et al. used the dataset from the Alzheimer's Disease 
Neuroimaging Initiative cohort and selected 1,563 non-Hispanic Caucasian 
participants to correlate different quantitative phenotypes (including hippocampal 
volume, metabolic activity, cerebrospinal fluid total tau level, amyloidosis in the 
hippocampus, and composite memory) with 18407 SNPs in 81 genes from a targeted 
neurogenesis pathway.105 The researchers showed that participants with at least one 
copy of the minor allele T of rs9608282 (located in the first intron of SPECC1L, 
upstream of ADORA2A) had a greater mean hippocampal volume and a greater 
neurogenesis-related hippocampal sub-region volume than participants bearing the 
other genotype. Horgusluoglu-Moloch et al. replicated these results in a meta-
analysis that included two other cohorts (adding 277 additional participants) and 
evidenced an association with better episodic memory performance, and with a low 
cerebrospinal fluid total tau level. These results suggest that ADORA2A has a role in 
neurogenesis in adults. However, an analysis of the BRAINEAC brain tissue 
microarray-based gene expression database (http://www.braineac.org/) found that 
rs9608282 is not associated with ADORA2A expression levels in the hippocampus. 
Future research will have to validate this SPECC1L SNP and assess its potential 
function in the adenosine-related pathway. 
Shinohara et al. identified an ADORA2A haplotype “A” (built from a C allele at 
rs2298383, a T allele at rs5751876, a deletion at rs35320474 and a C allele at 
rs4822492) as a risk factor for a severe form of encephalopathy in children following 
severe febrile seizures: acute encephalopathy with biphasic seizures and late 
reduced diffusion.14 The haplotype A was significantly more frequent in patients 
(n=85) than in controls (n=184). The most significant association was obtained in a 
recessive model (OR [95%CI]=2.32 [1.32-4.08]; p=0.003). The level of ADORA2A 
mRNA was 1.4-fold higher in the brain tissue of individuals with a homozygous 
haplotype A (i.e. diplotype AA), relative to individuals with AB or BB diplotypes. This 
finding was confirmed by the mRNA and protein expression levels measured in 
lymphoblasts. Lastly, the researchers evidenced greater cAMP accumulation in 
response to adenosine in lymphoblasts with the AA diplotype than in cells with the BB 
diplotype (p=0.0006). These results support the hypothesis whereby elevated 
expression of ADORA2A in children may alter the intracellular adenosine/cAMP 
signal cascade, enhance excitatory neurotransmitter release, and thus favor 
excitotoxicity. 
 
Neurologic traits 
Two studies have suggested that a TT genotype at rs5751876 is associated with 
greater sensitivity to sensory stimuli. Firstly, ADORA2A variants were associated with 
differences in the efficiency of pre-attentive sensory memory subprocesses.106 The 
researchers examined the results of a memory task after a visual stimulus in 199 
healthy participants. Although the initial visual availability of stimulus information was 
greater in participants carrying the rarer homozygous genotype (i.e. TT genotypes for 
rs5751876 and rs2298383), less information was transferred to the working memory. 
This finding suggests that pre-attentive sensory memory subprocesses are 
modulated by ADORA2A. Secondly, Geiger et al. correlated functional MRI and 
genotyping results in healthy human subjects.107 A TT genotype at rs5751876 
(associated with an elevated anxiety risk) was found to modulate a fronto-insular 
network involved in attention and in the processing of interoceptive and exteroceptive 
information; it was suggested that this modulation increases the likelihood of anxiety 
and anxiety disorders. 
In a pilot study of 19 healthy volunteers, Rupp et al. assessed the relationship 
between sleep restriction resistance and ADORA2A and PER3 genotypes.108 An 
rs5751876 TT genotype group (n=9) showed lower behavioral resiliency after sleep 
restriction than a group with the CT genotype (n=9). Several studies has confirmed 
the relationship between ADORA2A variants and sleep, with notably an association 
between genetic variants in ADORA2A (especially rs5751876) and individual 
sensitivity to sleep disturbance caused by caffeine consumption.109–112 
To conclude, the genetic variants in ADORA2A are the most studied among 
adenosine gene receptor. They are associated with a lot of CNS diseases or traits, 
but sometimes provided contradictory results.76,77 The most likely genetic 
associations concern HD, epilepsy, depression and anxiety disorders because of 
functional assessment of the variants, prospective design and/or studies on larger 
samples. However, efforts are needed to identify the true functional variant(s). 
 
 
ADORA2B  
Gene structure (Figure 1.C) 
The human ADORA2B gene was cloned from a human hippocampal cDNA library in 
1992.113 It spans 31 kb, and is located on chromosome 17p12.114,115 Although only a 
single copy of ADORA2B is present in the genome, a pseudogene (adenosine A2B 
receptor pseudogene 1, ADORA2BP1) was found on chromosome 1q32.2.115 
ADORA2BP1 is a processed pseudogene that lacks an intronic region. It may have 
been created during evolution by integration of ADORA2B mRNA into a chromosome 
break site, followed by DNA synthesis and repair. ADORA2B is composed of two 
coding exons and an intron. The gene comprises a 1756 bp CpG island 
encompassing the whole of exon 1 and the core promoter. The ADORA2B promoter 
contains binding sites for hypoxia-inducible factor 1-alpha,116,117 hypoxia-inducible 
factor 2-alpha,118 and Myb-related protein B.119 According to the GTEx database,25 
ADORA2B mRNAs are found in all tissues, with the highest expression levels in the 
skin, esophagus, vagina, colon, and anterior cingulate cortex. 
 
Genetic risk factor in human diseases 
ADORA2B has been highlighted as a potential modifier gene in prodromal HD with a 
variation in gray matter volume.11 After correcting for the effect of the disease burden 
effect (i.e. the number of HTT gene CAG repeats, and age), Liu et al. searched for 
genetic factors that influenced prodromal HD in a multicenter study including 715 
prodromal individuals. A GWAS did not reveal an association that remained 
significant after false discovery rate correction. However, a separate analysis of 
3,404 SNPs in 310 HD pathway genes evidenced a correlation between two SNPs in 
strong linkage disequilibrium (rs71358386 in NCOR1, and rs78804732 in ADORA2B 
intron 1) and the gray matter volume in the cuneus lobe; the presence of the minor 
alleles was correlated with a low gray matter volume. The major limitation consisted 
in the absence of correlation between SNPs and motor or cognitive function in 
prodromal individuals. Consequently, functional studies and longitudinal study in HD 
patients will be required to assess a modifier role of ADORA2B. 
 
 
ADORA3 
Gene structure (Figure 1.D)  
The human ADORA3 gene was first cloned in 1992.120,121 It is a short (4.3 kb) gene 
and is located on chromosome 1p13.2.122,123 It is composed of two exons and one 
intron,124 and encodes a single 318-aa protein. According to the GTEx database,25 
ADORA3 mRNAs expression levels are highest in the testis, spinal cord, adrenal 
gland, subtantia nigra, and spleen. 
The entire ADORA3 gene is encompassed by the first intron of the isoforms 2 to 4 of 
transmembrane and immunoglobulin domain containing 3 gene (TMIGD3). Moreover, 
isoform 1 of TMIGD3 shares its 5' terminal exon with almost all of the first exon of 
ADORA3. This alternative TSS results in a fusion product that includes the 116 N-
terminal amino acids of A3R. Data on TMIGD3 are scarce, although one study 
revealed a role for TMIGD3 isoform 1 as a suppressor of NF-κB and osteosarcoma 
progression.125 The ADORA3 gene’s promoter region has not been extensively 
studied but reportedly does not contain a TATA box; however, the existence of a 
CCAT box is subject to debate.126,127 Our analysis of the ADORA3 promoter region 
evidenced a CAAT box located 98 bp upstream of the TSS. Functional binding of 
Octamer-Binding Protein 1 and NF-κB transcription factors was found at the proximal 
part of the ADORA3 promoter region, and binding was inhibited by the rs1544224 
polymorphism (c.-564T>C, p.?) located in the 5'-UTR (encoded by exon 1).128 
 
Genetic risk factor in human diseases 
Prompted by A3R’s known role in the neuromodulation of serotonin (a 
neurotransmitter involved in many neuropsychiatric phenotypes, including autism), 
Campbell et al. examined a putative genetic link between rare coding variants of 
ADORA3 and autism. Using allelic association testing in 958 families (1,649 
probands; 4,150 samples), the researchers found no evidence supporting an 
association between a common variant at ADORA3 locus and ASD. However, in a 
case-control study including 185 unrelated ASD cases and 305 controls followed by a 
subsequent replication analysis of exome sequence data from 339 cases and pair-
matched controls,12 two rare coding variants (Leu90Val and Val171Ile) were 
significantly enriched in cases vs. controls. They were then assessed in vitro for their 
functional impact but showed incomplete penetrance and had opposite effects on 
antidepressant-sensitive 5-HT transporter activity. The relationship with disease was 
significant in the combined analysis using whole-exome sequencing data but not in 
the replication analysis. Taking into account replication data, only Leu90Val remain 
statistically significant (p=0.040). In total, Leu90Val was found in 4 patients among 
524 ASD cases and was absent in 644 control. The subjects in this study were not 
matched based on genome-wide genotype data. This limitation could constitute a 
bias, especially for the frequency of rare variants which can be very different between 
subgroups of a population with similar ethnicity. Such limitation is important regarding 
the small number of carriers. Although the researchers provided functional data of the 
two rare variants in cell culture, the association of rare ADORA3 variants and ASD 
should be interpreted with caution. Further studies in larger samples are needed to 
confirm this genetic association. 
 
 
Which genetic variants in adenosine receptors genes are functionally relevant? 
Despite their associations in several diseases, the functional effect of variants in 
adenosine receptors genes has been poorly described. The three more frequently 
studied ADORA2A SNPs (i.e. rs5751876, rs2298383 and rs35320474) and their 
associations with human brain diseases or traits are summarized in Table 2. The 
most-studied variant (rs5751876, c.1083T>C, p.(=)) is a synonymous variant that 
lacks a validated functional impact on protein function or synthesis. It has been 
suggested that several ADORA2A polymorphisms in linkage disequilibrium with 
rs5751876 are causal variants. For example, rs35320474 (c.*458dup, p.?, located in 
the 3'-UTR region of exon 4) has been discussed as a variant that might change 
A2AR expression.
81 Indeed, there is no data in favor of a transcriptional effect of 
rs35320474 in GTEx, but it modifies a U-rich motif. As these motifs can recruit RNA-
binding proteins, rs35320474 might modify the translation of ADORA2A mRNA. 
However, such functional effect has not been published for rs35320474. The second 
most intensively studied polymorphism in ADORA2A is the rs2298383 SNP (c.-
3206C>T, p.?), located in a regulatory triplex-forming oligonucleotide target 
sequence that has been conserved in mammals and is involved in the regulation of 
gene expression.129 It is also noteworthy that rs2298383 variant is located in the 
terminal 3’ exon of one of the isoforms of ADORA2A-AS1 and is associated with 
ADORA2A-AS1 mRNA expression.25 It is well known that antisense RNAs regulate 
gene expression on the opposite strand. Hence, it would be interesting to study the 
effect of rs2298383 on the mRNA expression of ADORA2A and ADORA2A-AS1. In 
line with a putative transcriptional effect, rs2298383 is also an expression quantitative 
locus associated with ADORA2A mRNA expression in diverse tissues including 
different regions of the brain (i.e. nucleus accumbens, amygdala, cortex and 
hippocampus) (https://gtexportal.org/home/snp/rs2298383).25 More precisely, the TT 
genotype is associated with increased ADORA2A mRNA. But these results are in 
contradiction with the functional studies reported by Shinohara et al. who found 
elevated A2AR mRNA and protein expression levels and protein activity with 
associated ADORA2A haplotype A, including the C allele of rs2298383.14 It is then 
probable that rs2298383, like the other variants in ADORA2A, only tag the true 
causal variant(s). In 2014, Hohoff et al. used positron emission tomography to 
investigate the influence of ADORA1 and ADORA2A SNPs on the in vivo distribution 
and availability of cerebral A1Rs in healthy humans.
130 
 Indeed, A1ARs and A2ARs are frequently co-expressed, and interact directly by 
heteromerization. Hohoff et al. observed that ADORA2A SNPs are associated with 
increased binding and availability of A1Rs in various regions of the brain. The CT and 
TT genotypes at rs2236624 are associated with greater distribution and availability of 
A1R in the superior frontal gyrus and dorsolateral prefrontal cortex, whereas the CT 
and TT genotypes at rs5751876 are associated with greater distribution and 
availability in the entorhinal cortex, hippocampus, and cortex as a whole. The brain 
regions associated with ADORA2A SNPs are involved in emotion processing, which 
might contribute to their effects on anxiety and panic disorder. The SNPs rs10920568 
and rs3766566 in ADORA1 also correlated with the in vivo distribution and availability 
of cerebral A1Rs. 
None of ADORA1 common variants rs3766553 and rs10920573 (associated with 
epilepsy after traumatic brain injury48) has been assessed during functional studies. 
We noted that rs10920573, located in intron 5, reported in the GTEx database,25 is 
associated with variation in expression of ADORA1 mRNA in the whole blood 
(p=8.8 e-15). Rarer allele T, and genotype TT of rs10920573 are associated with an 
increase of ADORA1 mRNA, but Wagner et al. found that it was the heterozygotes 
genotype CT that was at greatest risk of epilepsy which is not in favor of protective 
effect of either allele. Functional impact of the two SNPs reported by Liu et al. is not 
established and we even don't know which gene between ADORA2B and NCOR1 is 
implied in prodromal HD.11 NCOR1 and ADORA2A (but not ADORA2B) are part of 
the HD pathway, but it is noteworthy that SNP rs71358386 in NCOR1 regulates 
expression of ADORA2B (and not NCOR1) in various tissues including the brain 
cortex.25 Minor allele G of rs71358386 is negatively correlated to grey matter volume 
in the cuneus lobe and is associated with low ADORA2B mRNA.25 How a decrease 
in ADORA2B mRNA (and then probably in A2BR too) induces a decrease in grey 
matter and potentially favors HD progression is not fully understood. However, recent 
studies demonstrated the existence of brain A2AR-A2BR heteroreceptor complexes, 
that might inhibit neurodegeneration in models of brain diseases by A2AR 
inactivation.131 The functional effect of the rare coding variant Leu90Val in ADORA3 
was demonstrated in cell culture by Campbell et al. The researchers showed 
elevated basal cGMP levels and response to an A3AR agonist compared with the wild 
type receptor. Moreover, the cells transfected with ADORA3 and 5-HT transporter 
gene showed an increase in antidepressant-sensitive 5-HT transporter activity.12 
 
Conclusions 
The results of a large number of genetic studies suggest that variants in adenosine 
receptor genes are associated with neurologic or psychiatric diseases. However, 
most of the research performed to date has been based on small case-control 
studies. Without any functional evidence and replication in other populations, such 
studies do not provide enough evidences and must be interpreted with cautions 
because smaller sample size increase the risk that observations will be due to 
chance. The multiplication of genetic studies of recurrent genetic variants in multiple 
disorders, as seen for rs5751876 in psychiatric disorders, increases the risk of false-
positive too. It may explain the heterogeneity of the findings and for example why the 
incriminated allele of rs5751876 associated with panic disorder varies depending the 
studies76,77 or why ADORA2A is absent in larger studies like GWAS on anxiety 
disorder.132 However, there are too many genetic associations between ADORA2A 
SNPs and anxiety disorders to disregard them all. Moreover, a growing body of 
evidence suggested that A2AR influence the fear network
133 and bring rational 
explanations to these genetic associations. This is in line with the recent report of 
increased A1AR availability in regions of the fear network, in ADORA2A risk allele 
carriers.130  
The development of new study designs in genetic research has prompted renewed 
interest in specific phenotypes,14 cross-sectional population-based analysis15 and 
rare variants.12,13 The study of rare variant is of particular interest as it is based on 
the common disease-rare variant hypothesis, according an increasing role of rare 
variant in human complex diseases or traits.134 A screen for rare variants and/or the 
aggregation of variants in regulatory regions could also be interesting for ADORA2A 
because none of the SNPs reported to date have proved to be functional and may 
only be tags for one several rare variants in linkage disequilibrium. Such rare variants 
restricted to smaller groups of populations could also explain the ethnicity-dependent 
and/or heterogeneity of the findings concerning ADORA2A SNPs. 
In the future, genetic research should take account of a number of confounding 
factors (e.g. ethnicity and gender) and common gene-environment interactions (e.g. 
caffeine intake). Further studies are particularly needed to integrate the role of 
caffeine, a widely consumed antagonist of adenosine receptors, in HD,103 
depression135 and neuropsychiatric disorders.18  
Another major task relates to the characterization of the genes’ structure and 
regulatory mechanisms. Indeed, most of the structural specificities and genetic 
variants in the adenosine receptor genes do not lead to changes in the protein 
sequences or biochemical properties. However, adenosine receptor expression is 
frequently deregulated in a context of neurodegenerative disease. Thus, there is 
great interest in the role of adenosine receptor genes and their posttranslational 
regulation as it could be the key to understand the deregulations of adenosine 
receptors in many common neurodegenerative diseases. 
Lastly, there is a growing body of evidence suggesting a modulation of the 
neurodegenerative effects of A2AR through its interaction with other adenosine 
receptors.131 Further studies should include all robust associations in adenosine 
receptors genes, in related non-coding RNAs and in other relevant genes. For 
example, it would be interesting to study together variants in ADORA2A and in 
different genes implicated in adenosine metabolism or nucleoside transporter, such 
as the variants in SLC29A3 which are associated with altered adenosine transport 
and predispose to depression with disturbed sleep.136   
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Table 1. Adenosine receptor genes and proteins  
Official gene Name* Old Name Reference mRNA transcript# Protein name Protein length (aa) 
ADORA1  RDC7  NM_000674.2 A1R  326 
ADORA2A RDC8  NM_001278497.1 A2AR  412 
ADORA2B - NM_000676.2 A2BR  332 
ADORA3 - NM_000677.3 A3R  318 
 
* HUGO nomenclature; # the reference mRNA transcripts are the longest transcripts listed in the NCBI RefSeq database 
(GRCh37/Hg19) and encode the longest protein isoform. 
  
Table 2. Significant associations in brain diseases or traits of rs5751876, rs2298383 and rs35320474 in ADORA2A 
Associated brain diseases or traits 
Studied population Risk Risk 
Ref 
Patients Ethnicity Country allele genotype 
rs5751876 
Panic disorder 99 patients and 99 controls Caucasian Germany T TT 76 
Panic disorder 70 multiplex families and 83 triad families Caucasian* USA C  77 
Sympathetic measures during venipuncture 17 patients with blood-injury phobia Caucasian Germany  TT 78 
Panic disorder 457 patients and 457 controls Caucasian Germany T  19 
Panic disorder and agoraphobia 341 patients and 457 controls Caucasian Germany C  19 
Anxious personality trait 424 healthy participants Caucasian UK C  19 
Self-reported anxiety after caffeine administration 94 healthy participants Caucasian* USA  TT 81 
Self-reported anxiety after d-amphetamine administration 99 healthy participants n.a. USA  TT 83 
Self-reported anxiety after caffeine administration 416 healthy participants Caucasian UK  TT 37 
Startle reflex after caffeine administration 110 healthy participants Caucasian Germany  TT 84 
Prepulse inhibition/facilitation after caffeine administration 114 healthy participants Caucasian Germany  TT 85 
Decreased attention after caffeine administration 106 healthy participants Caucasian Italy  CC 86 
Decreased motor executive control after caffeine administration 106 healthy participants Caucasian Italy  TT 86 
Panic disorder patients with BS 92 patients BS+ and 259 BS- Caucasian USA T  90 
Tourette syndrome 162 patients and 270 controls Caucasian Poland T  34 
Tourette syndrome with concomitant ADHD 63 patients ADHD+ and 99 patients ADHD+ Caucasian Poland C  34 
Tourette syndrome with concomitant anxiety 34 patients anxiety+ and128 patients anxiety- Caucasian Poland C  34 
Increased autism-specific impairment 98 patients Caucasian Germany T  93 
Migraine with aura vs without aura 122 patients aura+ and 143 aura- Caucasian Germany C  99 
Earlier age of onset HD 791 HD patients Caucasian France  TT 100 
Earlier age of onset HD 419 HD patients Caucasian Germany  TT 101 
Earlier age of onset HD 18 HD patients n.a. Uruguay T  102 
Variation in pre-attentive sensory memory sub-processes 199 healthy participants Caucasian Germany  TT 106 
AESD 85 patients and 184 controls Asian Japan T  14 
Attention and processing of information 65 healthy participants Caucasian Germany  TT 107 
Lower behavioral resiliency after sleep restriction 20 healthy participants n.a. USA  TT 108 
Insomnia-like EEG pattern after caffeine administration 19 healthy participants Caucasian Switzerland  CC 109 
Sustained vigilant attention after prolonged wakefulness 45 healthy participants Caucasian Switzerland T  110 
Lower effect of caffeine on attention after prolonged wakefulness 45 healthy participants Caucasian Switzerland T  110 
Sensitive to caffeine’s effects on sleep 2402 healthy participants (1470 families) n.a. Australia C  111 
Sleep disturbance caused by caffeine consumption 926 healthy participants n.a. Brazil T  112 
A1AR availability in brain regions of fear network 28 healthy participants Caucasian Germany T  130 
rs2298383 
Anxious personality trait 424 healthy participants Caucasian UK T  79 
Self-reported anxiety after caffeine administration 102 healthy participants Caucasian* USA  CC 82 
Anxiety disorder in ADHD patients 478 ADHD patients Caucasian* Brazil  TT 92 
Autism spectrum disorder 98 patients and 234 controls Caucasian Germany  CC 93 
Earlier age of onset HD 419 HD patients Caucasian Germany  TT 101 
Variation in pre-attentive sensory memory sub-processes 199 healthy participants Caucasian Germany  CC 106 
AESD 85 patients and 184 controls Asian Japan C  14 
Sustained vigilant attention after prolonged wakefulness 45 healthy participants Caucasian Switzerland C  110 
Lower effect of caffeine on attention after prolonged wakefulness 45 healthy participants Caucasian Switzerland C  110 
rs35320474 
Self-reported anxiety after caffeine administration 94 healthy participants Caucasian* USA  Tins/Tins 81 
Self-reported anxiety after d-amphetamine administration 99 healthy participants n.a. USA  Tins/Tins 83 
ADHD traits 1747 twins Caucasian Sweden Tins  91 
Increased autism-specific impairment 98 patients Caucasian Germany del  93 
Migraine with aura vs without aura 122 patients aura+ and 143 aura- Caucasian Germany Tins  99 
Earlier age of onset HD 419 HD patients Caucasian Germany  del/del 101 
AESD 85 patients and 184 controls Asian Japan del  14 
Sustained vigilant attention after prolonged wakefulness 45 healthy participants Caucasian Switzerland del  110 
Lower effect of caffeine on attention after prolonged wakefulness 45 healthy participants Caucasian Switzerland del  110 
 
ADHD: attention deficit/hyperactivity disorder patients; AESD: Acute encephalopathy with biphasic seizures and late reduced 
diffusion; BS: bladder syndrome; HD: Huntington's disease; Ref: references; del: deletion; ins: insertion; n.a.: not available; *: mostly 
Caucasian. 
  
Figure legend 
Figure 1. Adenosine receptor genes in the human.  
Schematic representation of the (A) ADORA1, (B) ADORA2A, (C) ADORA2B, and 
(D) ADORA3 genes. Exons and introns are shown as boxes and horizontal lines, 
respectively. Untranslated regions are indicated as grey boxes, and coding exons are 
marked in black. The different TSSs are indicated by black perpendicular arrows. 
Transcripts with dotted lines correspond to mRNAs not fully sequenced or with low 
levels of evidence. Dotted boxes represent the CpG islands. Hatched boxes mark the 
relative location of the promoter region, according to the histone code and chromatin 
state segmentation data from the ENCODE project. 
  
Figure 1. Adenosine receptor genes in the human.  
  
Supplementary material 
Methods 
We searched the literature published in English from MEDLINE PubMed, Science 
Direct, Web of Science, Google Scholar, OMIM and the GWAS catalog 
(https://www.ebi.ac.uk/gwas/home) until 1 April 2019. We used the search terms 
("ADORA" or "Adenosine Receptor" or "ADORA1" or "RDC7" or "ADORA2A" or 
"A2aR" or "RDC8" or "ADORA2B" or "ADORA2" or "ADORA3" or "A3AR") AND 
("Variant*" or "SNP" or "Polymorphism*" or "Genotype" or "Haplotype" or "Allel*", or 
"Neurology" or "Psychiatry" or "Pharmacogenetics" or "Promoter" or "Exon" or 
"Intron" or "Splicing" or "Translation" or "Transcript*" or "Epigen*"). Bibliographies of 
the publications that met these criteria and of each relevant review were also 
manually screened to ensure no potential articles were missed. Publications included 
in this review involved at least one of the following criteria: (a) Adenosine receptor 
gene variation implied in a human genetic trait or pathology involving the central 
nervous system; (b) Adenosine receptor gene cloning, structure and transcription 
regulation. Exclusion criteria were defined as follows: papers addressing non-
neurological diseases or involving the peripheral nervous system, papers addressing 
only non-human genes. We excluded animal studies, conference proceedings, and 
editorials. 
 
 
